A 2-part Phase 1/2 Open-label Trial on ODM-212 (NCT07563738)
A 2-part Phase 1/2 Open-label Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ODM-212 in Combination With Anti-cancer Therapy in Participants With Advanced Solid Tumours
🩺 Plain-English Summary (8th-Grade Level)
An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
Who can join: Review the eligibility criteria below.
Location: NEXT Oncology — Irving, Texas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- NEXT Oncology — Irving, Texas
- NEXT Oncology Virginia — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: +358104261
Email: clinicaltrials@orionpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mesothelioma
- Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma — Baltimore, Maryland
- A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors — Los Angeles, California
- Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma — Tampa, Florida
- Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer — San Francisco, California
- Olaparib in Patients With HRD Malignant Mesothelioma — Chicago, Illinois
- A Study of Sacituzumab Govitecan in People With Mesothelioma — Basking Ridge, New Jersey
Explore by condition: All Mesothelioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.